JP2002508373A5 - - Google Patents

Download PDF

Info

Publication number
JP2002508373A5
JP2002508373A5 JP2000539019A JP2000539019A JP2002508373A5 JP 2002508373 A5 JP2002508373 A5 JP 2002508373A5 JP 2000539019 A JP2000539019 A JP 2000539019A JP 2000539019 A JP2000539019 A JP 2000539019A JP 2002508373 A5 JP2002508373 A5 JP 2002508373A5
Authority
JP
Japan
Prior art keywords
hydrate according
hydrate
diabetes
exhibits
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000539019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508373A (ja
Filing date
Publication date
Priority claimed from GBGB9726566.4A external-priority patent/GB9726566D0/en
Application filed filed Critical
Publication of JP2002508373A publication Critical patent/JP2002508373A/ja
Publication of JP2002508373A5 publication Critical patent/JP2002508373A5/ja
Withdrawn legal-status Critical Current

Links

JP2000539019A 1997-12-16 1998-12-14 医薬としての5−[4−[2−(n−メチル−n−(2−ピリジル)アミノ)エトキシ]ベンジル]チアゾリジン−2,4−ジオン・マレイン酸塩水和物 Withdrawn JP2002508373A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9726566.4A GB9726566D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical
GB9726566.4 1997-12-16
PCT/EP1998/008155 WO1999031095A1 (en) 1997-12-16 1998-12-14 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical

Publications (2)

Publication Number Publication Date
JP2002508373A JP2002508373A (ja) 2002-03-19
JP2002508373A5 true JP2002508373A5 (enExample) 2006-02-09

Family

ID=10823692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539019A Withdrawn JP2002508373A (ja) 1997-12-16 1998-12-14 医薬としての5−[4−[2−(n−メチル−n−(2−ピリジル)アミノ)エトキシ]ベンジル]チアゾリジン−2,4−ジオン・マレイン酸塩水和物

Country Status (35)

Country Link
EP (2) EP1661895A1 (enExample)
JP (1) JP2002508373A (enExample)
KR (1) KR100549142B1 (enExample)
CN (3) CN1281453A (enExample)
AP (1) AP1365A (enExample)
AR (1) AR017214A1 (enExample)
AU (1) AU1967999A (enExample)
BG (1) BG64988B1 (enExample)
BR (1) BR9813600A (enExample)
CA (1) CA2314107A1 (enExample)
CO (1) CO4980880A1 (enExample)
CZ (1) CZ299965B6 (enExample)
DZ (1) DZ2681A1 (enExample)
EA (1) EA004260B1 (enExample)
EG (1) EG22337A (enExample)
GB (1) GB9726566D0 (enExample)
HR (1) HRP20000408B1 (enExample)
HU (1) HUP0100509A3 (enExample)
IL (1) IL136424A (enExample)
IN (1) IN192487B (enExample)
MA (1) MA26580A1 (enExample)
MY (1) MY135612A (enExample)
NO (1) NO317254B1 (enExample)
OA (1) OA11766A (enExample)
PE (1) PE20000058A1 (enExample)
PL (1) PL341146A1 (enExample)
RS (1) RS50126B (enExample)
SA (1) SA99191115B1 (enExample)
SK (1) SK286618B6 (enExample)
TR (2) TR200001799T2 (enExample)
TW (1) TW509690B (enExample)
UA (1) UA72198C2 (enExample)
UY (2) UY25304A1 (enExample)
WO (1) WO1999031095A1 (enExample)
ZA (1) ZA9811506B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
RS50114B (sr) 1999-04-23 2009-03-25 Smithkline Beecham P.L.C., Novi polimorfni oblik 5-/4-/2-(n-metil- n-(2-piridil)amino/ etoksi/benzil/ tiazolidin-2,4-dion, soli maleinske kiseline
CN1167702C (zh) * 1999-04-23 2004-09-22 史密丝克莱恩比彻姆有限公司 5-[4-[2-n-甲基-n-(2-吡啶基)氨基]乙氧基]苄基]噻唑烷-2,4-二酮马来酸盐的多晶型物
EA003031B1 (ru) * 1999-04-23 2002-12-26 Смитклайн Бичам Плс Новый фармацевтический препарат
CN1426402A (zh) * 2000-04-25 2003-06-25 杏林制药株式会社 噻唑烷二酮衍生物的新颖的稳定晶体及其制法
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
AU9123201A (en) * 2000-09-26 2002-04-08 Reddy S Res Foundation Novel polymorphic forms of 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,4-dione maleate and process for their preparation
KR20030082541A (ko) * 2000-09-26 2003-10-22 닥터 레디스 레보러터리즈 리미티드 5-[4-[2-[엔-메틸-엔-(2-피리딜)아미노]에톡시]벤질]티아졸리딘 4-디온 말레이트의 신규의 다형상 및 그제조방법
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002350965A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
SG47100A1 (en) * 1994-02-10 1998-03-20 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases

Similar Documents

Publication Publication Date Title
JP2002508371A5 (enExample)
JP2002508373A5 (enExample)
TWI322686B (en) Compound and pharmaceutical composition for large conductance calcium-activated k channel opener
JP2002508372A5 (enExample)
JP5269758B2 (ja) 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体
EP2203433B1 (en) 5-(4-(2-(3-methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione for use in treating diabetes
TW487709B (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, its preparation and its use
JP2002535401A5 (enExample)
JP5149271B2 (ja) 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
JP2002519425A5 (enExample)
JP2005539053A5 (enExample)
WO2005077368A2 (en) Treatment of gastro-esophageal reflux disease (gerd)
JP2004535466A5 (enExample)
JP2005517006A5 (enExample)
JP2003516310A (ja) 新規治療方法
JP2009506014A5 (enExample)
JP2008534453A5 (enExample)
EA200101121A1 (ru) Полиморф 5-[4-[2-(n-метил-n-(2-пиридил) амино) этокси] бензил] тиазолидин-2,4-диона, соли малеиновой кислоты
TW509690B (en) Hydrate of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt, its preparation and its use
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
US8153804B2 (en) Aryl pyridines and methods of their use
EA200101119A1 (ru) Новый фармацевтический препарат
CA2554616A1 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
CA2202484C (en) Use of indole derivatives for the treatment of various diseases
JP2005516035A5 (enExample)